Zura Bio Limited (NASDAQ:ZURA) is Great Point Partners LLC’s 10th Largest Position

Great Point Partners LLC trimmed its position in Zura Bio Limited (NASDAQ:ZURA) by 29.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,263,672 shares of the company’s stock after selling 1,378,569 shares during the quarter. Zura Bio makes up 3.9% of Great Point Partners LLC’s investment portfolio, making the stock its 10th largest position. Great Point Partners LLC owned approximately 4.86% of Zura Bio worth $13,251,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new stake in Zura Bio in the second quarter valued at $43,000. Renaissance Technologies LLC raised its position in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares in the last quarter. SG Americas Securities LLC acquired a new position in Zura Bio in the third quarter valued at approximately $62,000. The Manufacturers Life Insurance Company acquired a new stake in Zura Bio during the third quarter worth approximately $71,000. Finally, Valence8 US LP purchased a new stake in shares of Zura Bio during the 3rd quarter worth approximately $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. This trade represents a 2.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently commented on ZURA. Piper Sandler reiterated an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th. HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Monday, November 18th. Chardan Capital cut their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.80.

Zura Bio Price Performance

NASDAQ ZURA opened at $3.01 on Wednesday. Zura Bio Limited has a 52-week low of $2.00 and a 52-week high of $6.35. The firm has a 50-day moving average price of $4.13 and a 200 day moving average price of $4.04.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, analysts predict that Zura Bio Limited will post -0.65 EPS for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.